[1]
|
Carlson, E.E. (2010) Natural products as chemical probes. ACS Chemical Biology, 5, 639-653.
doi:10.1021/cb100105c
|
[2]
|
Hu Lonser, R.R., Glenn, G.M., Walther, M., Chew, E.Y., Libutti, S.K., Linehan, W.M., et al. (2003) Von Hippel- Linda disease. Lancet, 361, 2059-2067.
doi:10.1016/S0140-6736(03)13643-4
|
[3]
|
Iliopoulos, O., Levy, A.P., Jiang, C., Kaelin Jr., W.G. and Goldberg, M.A. (1996) Negative regulation of hypoxia inducible genes by the von Hippel-Lindau protein. Proceedings of the National Academy of Science of the United States of America, 93, 10595-10599.
doi:10.1073/pnas.93.20.10595
|
[4]
|
Iliopoulos, O., Kibel, A., Gray, S. and Kaelin Jr., W.G., (1995) Tumour suppression by the human von Hippel- Lindau gene product. Nature Medicine, 1, 822-826.
doi:10.1038/nm0895-822
|
[5]
|
Zanella, F., Rosado, A., Blanco, F., Henderson, B.R., Carnero, A. and Link, W. (2007) An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays. ASSAY and Drug Development Technologies, 5, 333-341.
doi:10.1089/adt.2007.058
|
[6]
|
Haney, S.A., LaPan, P., Pan, J. and Zhang, J. (2006) High-content screening moves to the front of the line. Drug Discovery Today, 11, 889-894.
doi:10.1016/j.drudis.2006.08.015
|
[7]
|
Zanella, F., Lorens, J.B. and Link, W. (2010) High content screening: Seeing is believing. Trends in Biotechnology, 28, 237-245. doi:10.1016/j.tibtech.2010.02.005
|
[8]
|
Liptrot, C. (2001) High content screening—From cells to data to knowledge. Drug Discovery Today, 6, 832-834.
|
[9]
|
Sutphin, P.D., Chan, D.A., Li, J.M., Turcotte, S., Krieg, A.J. and Giaccia, A.J. (2007) Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells. Cancer Research, 67, 5896-5905.
doi:10.1158/0008-5472.CAN-07-0604
|
[10]
|
Turcotte, S., Sutphin, P.D. and Giaccia, A.J. (2008) Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: A novel molecule that induces autophagic cell death. Autophagy, 4, 944-946.
|
[11]
|
Dolma, S., Lessnick, S.L., Hahn, W.C. and Stockwell, B.R. (2003) Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell, 3, 285-296.
doi:10.1016/S1535-6108(03)00050-3
|
[12]
|
Giaccia, A., Siim, B.G. and Johnson, R.S. (2003) HIF-1 as a target for drug development. Nature Reviews Drug Discovery, 2, 803-811. doi:10.1038/nrd1199
|
[13]
|
Kaelin Jr., W.G. (2005) The concept of synthetic lethality in the context of anticancer therapy. Nature Reviews Cancer, 5, 689-698. doi:10.1038/nrc1691
|
[14]
|
Sutphin, P.D., Chan, D.A. and Giaccia, A.J. (2004) Dead cells don’t form tumors: HIF-dependent cytotoxins. Cell Cycle, 3, 160-163. doi:10.4161/cc.3.2.617
|
[15]
|
Gnarra, J.R., Lerman, M.I., Zbar, B. and Linehan, W.M. (1995) Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Seminars in Oncology, 22, 3-8.
|
[16]
|
Gossage, L. and Eisen, T. (2010) Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nature Reviews Clinical Oncology, 7, 277-288.
doi:10.1038/nrclinonc.2010.42
|
[17]
|
Milella, M. and Felici, A. (2011) Biology of metastatic renal cell carcinoma. Journal of Cancer, 2, 369-373.
doi:10.7150/jca.2.369
|
[18]
|
Turcotte, S., Chan, D.A., Sutphin, P.D., Hay, M.P., Denny, W.A. and Giaccia, A.J. (2008) A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell, 14, 90-102.
doi:10.1016/j.ccr.2008.06.004
|
[19]
|
Cowey, C.L., Sonpavde, G. and Hutson, T.E. (2010) New advancements and developments in treatment of renal cell carcinoma: Focus on pazopanib. Journal of OncoTargets and Therapy, 3, 147-155. doi:10.2147/OTT.S12480
|
[20]
|
Xu, C.F., Reck, B.H., Xue, Z., Huang, L., Baker, K.L., Chen, M., et al. (2010) Pazopanib-induced hyperbilirubinemia is associated with Gilbert’s syndrome UGT1A1 polymorphism. British Journal of Cancer, 102, 1371- 1377. doi:10.1038/sj.bjc.6605653
|
[21]
|
Linehan, W.M., Bratslavsky, G., Pinto, P.A., Schmidt, L.S., Neckers, L., Bottaro, D.P., et al. (2010) Molecular diagnosis and therapy of kidney cancer. Annual Review of Medicine, 61, 329-343.
doi:10.1146/annurev.med.042808.171650
|
[22]
|
Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Oudard, S., et al. (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 27, 3584-3590.
doi:10.1200/JCO.2008.20.1293
|
[23]
|
Yang, J.C., Haworth, L., Sherry, R.M., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New England Journal of Medicine, 349, 427-434.
doi:10.1056/NEJMoa021491
|
[24]
|
Wilhelm, S.M., Adnane, L., Newell, P., Villanueva, A., Llovet, J.M. and Lynch, M. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics, 7, 3129-3140.
doi:10.1158/1535-7163.MCT-08-0013
|
[25]
|
Escudier, B., Eisen, T., Stadler, W.M., Szczylik, C., Oudard, S., Staehler, M., et al. (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. Journal of Clinical Oncology, 27, 3312-3318. doi:10.1200/JCO.2008.19.5511
|
[26]
|
Hudson, C.C., Liu, M., Chiang, G.G., Otterness, D.M., Loomis, D.C., Kaper, F., et al. (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Molecular and Cellular Biology, 22, 7004-7014.
doi:10.1128/MCB.22.20.7004-7014.2002
|
[27]
|
Thomas, G.V., Tran, C., Mellinghoff, I.K., Welsbie, D.S., Chan, E., Fueger, B., et al. (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nature Medicine, 12, 122-127.
doi:10.1038/nm1337
|
[28]
|
Motzer, R.J., Escudier, B., Oudard, S., Hutson, T.E., Porta, C., Bracarda, S., et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet, 372, 449-456. doi:10.1016/S0140-6736(08)61039-9
|
[29]
|
Robinson, J.P. (1998) Current protocols in cytometry. John Wiley and Sons, Inc., New York, 9.11.1-9.11.9.
|